GlassScriptPhysician profile
Sanjeev Kota
NPI 1447416557
$1,191.81
in general payments reported to CMS, 2019-2025
12 companies · $278 in 2025
The $278 reported for 2025 was more than what 83% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $83.88 · 2021: $16.34 · 2022: $18.16 · 2023: $152 · 2024: $246 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $529.74 | 2023-2025 | Azstarys |
| Pfizer INC. | $186.62 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $108.02 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $78.57 | 2019 | |
| Merck Sharp & Dohme LLC | $73.08 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Takeda Pharmaceuticals U.S.A., INC. | $49.99 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $48.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $44.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $36.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.42 | 2019 | |
| Novo Nordisk INC | $11.59 | 2019 | |
| Organon LLC | $6.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Kota listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.